UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday afternoon, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Britain's Antstream is jumping into the cloud gaming battle with a streaming platform for retro titles. And Tencent just backed the company.Technologyread more
American comedian Hannibal Buress, who stars in "The Eric Andre Show," has made a recent transition into the world of business as an angel investor — but there's an important...How I Made Itread more
Former Food and Drug Administration Commissioner Scott Gottlieb defended his decision to join Pfizer's board of directors just two months after stepping down from the agency that regulates the drugmaker. He said in an interview Tuesday on CNBC he feels "very confident" about his record at the FDA and is "very proud" of his new role.
Pfizer last week announced Gottlieb would join its board of directors — a job that paid a minimum of $335,000 in stock and cash in 2018, according to a regulatory filing. At the FDA, Gottlieb called for promoting innovation and increasing competition to lower prescription drug prices.
"I feel very confident about my record at the agency, and I called balls and strikes and acted in the interest of public health and public interest," Gottlieb said in an interview on CNBC's "Squawk Box."
Gottlieb, who is a medical doctor, previously worked in the biotech sector as a venture capitalist. "I've largely returned to my work prior to the FDA," he said.
Since leaving the agency, Gottlieb has returned to the American Enterprise Institute as a resident fellow and as a special partner at venture capital firm New Enterprise Associates, where he worked before joining the FDA. He also joined CNBC as a contributor.
It's not uncommon for government officials to join the sector they regulated after leaving the administration. However, President Donald Trump, who appointed Gottlieb, has made "draining the swamp" one of his main priorities.
"I worked with some large drugmakers before I came into the agency," Gottlieb said, adding that his new role at Pfizer is bigger than anything he did before the FDA. "I made no bones about the fact that I had expertise in life sciences and I made my living trying to promote innovation in this sector prior to coming to the agency."
Disclosure: Scott Gottlieb is a CNBC contributor.